<DOC>
	<DOCNO>NCT00452504</DOCNO>
	<brief_summary>This first-in-humans study SRA-444 . This study provide initial assessment safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) SRA-444 ( SR formulation ) administration ascend single oral dos healthy adult subject .</brief_summary>
	<brief_title>Single Ascending Dose Study SRA-444 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Healthy men woman nonchildbearing potential age 18 50 year , Body mass index range 18 30 kg/m2 body weight ≥50 kg . Exclusion criterion : Family history sudden death and/or QT prolongation . An automatic ECG correct QT ( QTc ) interval read screen &gt; 450 m &gt; 470 m male female subject , respectively . Sinus bradycardia screening , define rest heart rate ≤45 bpm . Resting supine blood pressure screen &lt; 110 mm Hg ( systolic ) and/or &lt; 60 mm Hg ( diastolic ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>